

RESEARCH ARTICLE

Induction of antitumor immunity against mouse carcinoma by baculovirus-infected dendritic cells

Tomoyuki Suzuki¹, Myint Oo Chang², Masayuki Kitajima³ and Hiroshi Takaku^{1,2}

A dendritic cell (DC) vaccine strategy has been developed as a new cancer immunotherapy, but the goal of complete tumor eradication has not yet been achieved. We have previously shown that baculoviruses potently infect DCs and induce antitumor immunity against hepatomas in a mouse model. Baculovirus-infected, bone marrow-derived DCs (BMDCs) display increased surface expression of costimulatory molecules, such as CD80, CD86 and major histocompatibility complex (MHC) classes I and II, and secrete interferons and other proinflammatory cytokines. In this study, we evaluated the induction of antitumor immunity in mice by baculovirus-infected BMDCs against lung cancer and melanoma. After treatment with baculovirus-infected BMDCs, murine lung tumors caused by Lewis lung carcinoma (LLC) cells were significantly reduced in size, and the survival of the mice was improved. In addition, experiments using a melanoma mouse model showed that baculovirus-infected BMDCs inhibited tumor growth and improved survival compared with controls. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and creatinine levels remained normal in baculovirus-infected BMDC-treated mice. Our findings show that baculovirus-infected DCs induce antitumor immunity and pave the way for the use of this technique as an effective tool for DC immunotherapy against malignancies.

Cellular & Molecular Immunology advance online publication, 27 September 2010; doi:10.1038/cmi.2010.48

Keywords: dendritic cells; natural killer cells; T cells; tumor immunity

INTRODUCTION

Dendritic cells (DCs) play a major role as professional antigen-presenting cells in the activation of natural killer (NK) cells, T cells and B cells. In particular, DCs are important in the initiation of innate and adaptive immune responses against tumors and invading pathogens. Recently, DC vaccination has been reported as a new immunotherapeutic strategy for the treatment of cancers.¹ However, very few clinical studies using DC immunotherapy have been reported, and those studies demonstrated insufficient efficacy.

The baculovirus *Autographa californica* multiple nuclear polyhedrosis virus, is an enveloped insect virus that has a 130-kb double-stranded circular DNA genome.² Baculoviruses have long been used as biopesticides^{3,4} and recombinant protein expression systems.^{5,6} Recent research has focused on the use of baculoviruses as vectors in gene therapy because of (1) their ability to infect, but not replicate in, mammalian cells; (2) their low cytotoxicity; and (3) their ability to carry large foreign genes into their genome.^{7–10} In several reports, baculoviruses were developed as vaccines against pathogens.^{11–15} Abe *et al.* reported that baculovirus-infected host cells produced type I interferons and proinflammatory cytokines through Toll-like receptor 9 and interferon regulatory factor 7 signaling.^{16,17} Schütz *et al.* reported that baculovirus-infected, human monocyte-derived DCs expressed cell-surface activation markers and produced tumor-necrosis factor alpha (TNF- α).¹⁸ In addition, Hervas-Stubbs *et al.*

reported that baculoviruses strongly induced the secretion of type I interferon and proinflammatory cytokines in mice.¹⁹ Conventional splenic DCs and plasmacytoid DCs displayed upregulation of surface major histocompatibility complexes (MHCs) and costimulatory molecules in response to baculovirus infection *in vivo*. Jordan *et al.* demonstrated that vaccination with insect cells infected with recombinant, baculovirus-encoding peptide–MHC complexes generated peptide-specific cytotoxic T-cell responses and antitumor immunity.²⁰ We have previously described the induction of antitumor effects using wild-type baculovirus in a mouse model of hepatoma.²¹ In particular, DCs were more potently infected by baculovirus than were other immune cells, and the DCs underwent activation and maturation. Baculovirus-infected bone marrow-derived dendritic cells (BMDCs) (BV-DCs) showed upregulation of costimulatory molecules, such as CD80, CD86 and MHC classes I and II, and increased secretion of interferons and other proinflammatory cytokines.²²

In this study, we showed that the inoculation of BV-DCs induced efficient CD8⁺ T cell- and NK cell-dependent, CD4⁺ T cell-independent antitumor immunity. Furthermore, BV-DC administration did not cause any functional damage to the mouse liver or kidneys. Our results demonstrate that BV-DC-induced antitumor immunity *in vivo* has strong potential as a future DC immunotherapy against various malignancies.

¹Department of Life and Environmental Sciences, Chiba Institute of Technology, Chiba, Japan; ²High Technology Research Center, Chiba Institute of Technology, Chiba, Japan and ³Immunology Program, Benaroya Research Institute, Seattle, WA, USA

Correspondence: Professor H Takaku, Department of Life and Environmental Sciences, Chiba Institute of Technology, 2-17-1 Tsudanuma, Narashino, Chiba 275-0016, Japan. E-mail: hiroshi.takaku@it-chiba.ac.jp

Received 19 June 2010; revised 2 August 2010; accepted 11 August 2010

MATERIALS AND METHODS

Mice, cell lines and reagents

Female C57BL/6 mice (6 weeks old) were purchased from Nippon SLC (Hamamatsu, Japan) and maintained under humane conditions according to the rules and regulations of our institutional committee. *Spodoptera frugiperda* (Sf-9) cells were cultured at 27 °C in Sf-900 II medium (Invitrogen, Carlsbad, CA, USA). Lewis lung carcinoma (LLC), B16F10 and EL4 cells were obtained from the RIKEN Cell Bank (Wako, Saitama, Japan). LLC and EL4 were maintained in Dulbecco's modification of Eagle's medium (Invitrogen) supplemented with 10% fetal calf serum (Sigma Chemical, St Louis, MO, USA), 100 U/ml penicillin, and 100 µg/ml streptomycin (Sigma Chemical). B16F10 cells were maintained in RPMI-1640 (Invitrogen) supplemented with 10% fetal calf serum. Synthesized phosphorothioate-stabilized mouse type A CpG oligodeoxynucleotides (CpG-A: ODN-D19) (GGTGCATCGATGCAGGGGG) were purchased from Hokkaido System Science (Sapporo, Hokkaido, Japan). Recombinant murine granulocyte-macrophage colony-stimulating factor, murine IL-4 and human IL-2 were obtained from PeproTech EC Ltd (London, UK).

Purification of wild-type baculovirus

Wild-type baculovirus was purchased from BD Biosciences (San Jose, CA, USA) and propagated in Sf-9 cells in Sf-900 II medium. The baculovirus was purified as previously described,²¹ and the virus titer was determined by the plaque assay.

Generation of murine BMDCs

Murine BMDCs were generated as described previously.²³ Briefly, bone marrow cells were harvested from the tibiae and femurs of C57BL/6 mice and depleted of red blood cells using red blood cell lysis buffer (Sigma Chemical). Bone marrow cells were cultured in RPMI-1640 medium containing 10% fetal calf serum, 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine (Invitrogen) and 50 µM 2-mercaptoethanol (Invitrogen), supplemented with 20 ng/ml each of murine granulocyte-macrophage colony-stimulating factor and IL-4. On days 3 and 5, the culture medium was replaced with fresh medium that was supplemented with murine granulocyte-macrophage colony-stimulating factor and IL-4 at the same concentration. On day 7, non-adherent and loosely adherent cells were collected and positively selected with anti-mouse CD11c microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany).

Baculovirus infection of BMDCs

BMDCs (1×10^6 cells) were infected with wild-type baculovirus at a multiplicity of infection (MOI) of 50 or incubated with CpG (1 µM) as a control for 1 h at 37 °C. Next, the cells were washed twice with sterile physiological saline and cultured for 5 h at 37 °C. The cells were then harvested, thoroughly washed twice with physiological saline and resuspended in 100 µl of physiological saline. To determine the presence of viral protein in BMDCs, cells were collected at 1 and 3 h after infection and lysates were assayed by western blot analysis using anti-gp64 monoclonal antibody that targeted the baculoviral envelope. The result indicated the complete degradation of baculovirus 3 h post-infection in BMDCs (Supplementary Figure 1).

DC-induced immunity against LLC *ex vivo*

LLC cells (1×10^6 cells/mouse) were intravenously injected into mice on day 0, followed by intravenous injection of (1×10^6 cells/mouse) of immature BMDCs (iDCs), CpG (1 µM)-treated BMDCs (CpG-DCs), wild-type BV-DCs (MOI=50) or (5×10^7 plaque-forming unit (pfu)/

mouse) of wild-type baculovirus on day 3. Twenty-eight days after injection, all mice were killed, and cancer nodules on both lungs were counted. Lung tissue was then fixed with formalin (10%) and embedded in paraffin. The paraffin sections were stained with hematoxylin and eosin.

Cytotoxicity assay against LLC

LLC cells (1×10^6 cells/mouse) were intravenously injected into mice on day 0, followed by intravenous injection (1×10^6 cells/mouse) of iDCs, CpG-DCs or BV-DCs (MOI=50) on day 3. Twenty-eight days after injection, the mice were killed, and splenocytes were harvested. Splenocytes were cocultured with target cells (LLC or EL4) after treatment with mitomycin C (10 µg/ml) at effector/target ratios of 100:1, 50:1 and 25:1 in the presence of recombinant human IL-2 (100 IU/ml). After 5 days, the cytotoxicity was assessed using the CytoTox 96 Non-Radioactive Cytotoxicity Assay Kit (Promega, Madison, WI, USA) according to the manufacturer's protocol.

Ex vivo DC therapy against B16F10 cells

B16F10 cells (1×10^6 cells/mouse) were subcutaneously injected into mice on day 0, followed by intratumoral injections (1×10^6 cells/mouse) of iDCs, CpG-DCs or BV-DCs (MOI=50) on days 10, 17 and 24. Mice were injected with each type of BMDCs when the tumor diameters reached 7–9 mm. The tumor volume was measured every 3 days.

Cytotoxicity assay against B16F10

B16F10 cells (1×10^6 cells/mouse) were subcutaneously injected into mice on day 0, followed by intratumoral injection (1×10^6 cells/mouse) of iDCs, CpG-DCs or BV-DCs (MOI=50) on day 10. Seventeen days after injection, the mice were killed, and splenocytes were harvested. Splenocytes were cocultured with target cells (B16F10 or EL4) after treatment with mitomycin C (10 µg/ml) at effector/target ratios of 100:1, 50:1 and 25:1 in the presence of recombinant human IL-2 (100 IU/ml). After 5 days, the cytotoxicity was assessed using the CytoTox 96 Non-Radioactive Cytotoxicity Assay Kit (Promega) according to the manufacturer's protocol.

In vivo depletion of CD4⁺, CD8⁺ or NK cells

To deplete CD4⁺ and CD8⁺ T cells *in vivo*, mice were intraperitoneally injected with the ascites fluid (100 µl/mouse) from CD4⁺ or CD8⁺ hybridoma-bearing mice (clone GK1.5 or 2.43) on days 6, 9, 12, 15, 18 and 21 after tumor inoculation. To deplete NK cells, anti-asialo GM1 antibody (50 µl/mouse; Wako Pure Chemical Industries, Osaka, Japan) was intraperitoneally injected on days 6 and 9 after tumor inoculation. Flow cytometry analysis confirmed >90% depletion of the target cells.

Measurement of serum aspartate aminotransferase (AST), alanine aminotransferase (ALT) and creatinine

Wild-type baculovirus (5×10^7 pfu/mouse) or BV-DCs (1×10^6 cells/mouse) were intravenously injected into mice. After 24 h, the sera were collected, and AST, ALT and creatinine levels were measured using the Transaminase CII-Test Wako (Wako Pure Chemical Industries) and the Creatinine Parameter Assay kits (R&D systems, Minneapolis, MN, USA) according to the manufacturer's protocols.

Statistical analyses

Statistical analyses were performed using Student's *t*-test. The mouse survival rates were analyzed using the log-rank test.

RESULTS

Antitumor effects of BV-DCs against lung cancer

Baculovirus infection of mouse splenic or BMDCs upregulated the expression of activation markers and the secretion of interferon- α and proinflammatory cytokines.^{19,21,22} We have previously described the induction of antitumor immunity by wild-type baculovirus in a mouse hepatoma model. We also showed that BV-DCs upregulated the expression of MHC and costimulatory molecules and increased the secretion of type I interferons and proinflammatory cytokines.²² Moreover, NK cells or T cells cocultured with BV-DCs produced interferon- γ and demonstrated increased cytotoxicity and proliferation. Here, we first evaluated the effects of antitumor immunity against murine lung cancer. The experimental schedule is shown in Figure 1a. Mice were inoculated with LLC cells and immunized 3 days later with iDCs, CpG-DCs, BV-DCs or wild-type baculovirus. CpG oligodeoxynucleotides and baculovirus were recognized by Toll-like receptor 9, and CpG-stimulated DCs showed upregulation of MHC and costimulatory molecules and increased secretion of proinflammatory cytokines, except type I interferons.^{16,22,24} Twenty-eight days after immunization, the mice were killed and evaluated for lung tumors. In comparison with non-immunized or iDC-immunized mice, tumor

nodules in BV-DC-immunized mice were reduced to nearly the same extent as those in CpG-DCs and wild-type baculovirus-immunized mice (Figure 1b and c). As shown in Figure 1d, histological examination of the tumor tissues in the tumor-bearing, non-immunized or iDC-immunized mice showed bleeding and necrosis of the tumor tissues with partial infiltration of neutrophils and lymphocytes, but BV-DC- and CpG-DC-immunized mice displayed normal lung histology without tumor formation. Survival was also prolonged in BV-DC-immunized mice as compared with that in the other groups (Figure 2a). Cytotoxicity was assessed for each group of mice, and the splenocytes of BV-DC-immunized mice demonstrated upregulation of cytotoxicity against LLC cells as compared with the other groups (Figure 2b). NK cell-resistant EL4 cells were used as target cells in a control experiment, and negative results were obtained (Figure 2c). These results indicate that BV-DC-induced antitumor activity against mouse lung cancer was due to the cytotoxic effects of both NK and CD8⁺ T cells.

Antitumor effects of BV-DCs against melanoma

We next examined whether the BV-DCs could induce antitumor immunity against established subcutaneous tumors in mice. The




Figure 1 BV-DCs mediate antitumor immunity against LLC lung cancer. LLC cells were intravenously injected into mice (1×10^6 cells/mouse) on day 0, followed by one intravenous injection (1×10^6 cells/mouse) of iDCs, CpG-DCs, BV-DCs or wild-type baculovirus (5×10^7 pfu/mouse) on day 3. (a) Experimental design used to assess the antitumor immunity conferred by various DCs. (b) Dot plots indicate the number of nodules of LLC following treatment with various DCs or wild-type baculovirus, 28 days after tumor cell inoculation. * $P < 0.01$, compared with the negative control and iDC treatment. ** $P > 0.05$, compared with the CpG-DC and wild-type baculovirus treatment. (c) Images of lungs excised from tumor-bearing mice 28 days after various DC and wild-type baculovirus treatments. (d) Hematoxylin and eosin-stained tissue sections of the excised lungs. Similar results were obtained in two independent experiments. BV, baculovirus; BV-DC, baculovirus-infected bone marrow-derived dendritic cell; CpG-DC, CpG ($1 \mu\text{M}$)-treated bone marrow-derived dendritic cell; DC, dendritic cell; iDC, immature dendritic cell; LLC, Lewis lung carcinoma; MOI, multiplicity of infection; NC, negative control; pfu, plaque forming unit.




Figure 2 BV-DCs increased the survival of LLC tumor-bearing mice and showed increased cytotoxicity against LLC cells. LLC cells were intravenously injected into mice (1×10^6 cells/mouse) on day 0, followed by one intravenous injection (1×10^6 cells/mouse) of immature iDCs, CpG-DCs or BV-DCs on day 3. (a) Survival rate of LLC lung metastasis-bearing mice treated with various DCs. * $P < 0.01$, compared with the negative control and iDC treatment. ** $P > 0.05$, compared with the CpG-DC treatment. Splenocytes were isolated from immunized mice 28 days after BMDC immunization, and a cytotoxicity assay was performed. Cytotoxicity against LLC (b) or EL4 cells (c) by splenocytes from tumor-bearing mice treated with various BMDCs. Similar results were obtained in two independent experiments. BMDC, bone marrow-derived dendritic cell; BV-DC, baculovirus-infected bone marrow-derived dendritic cell; CpG-DC, CpG ($1 \mu\text{M}$)-treated bone marrow-derived dendritic cell; DC, dendritic cell; iDC, immature dendritic cell; LLC, Lewis lung carcinoma; NC, negative control.

experimental schedule is shown in Figure 3a. Mice were inoculated with B16F10 tumor cells and immunized 10, 17 and 24 days later with iDCs, CpG-DCs or BV-DCs. As shown in Figure 3b and c, BV-DCs inhibited tumor growth as compared with the other control BMDCs. The survival time of the mice immunized with BV-DCs was significantly prolonged as compared with that of the mice inoculated with control BMDCs (Figure 3d). Cytotoxicity was assessed for each group of mice, and BV-DC-inoculated mouse splenocytes demonstrated an upregulation of cytotoxicity against B16F10 cells as compared with the other groups (Figure 4a). EL4 cells were used as target cells in a control experiment, and negative results were obtained (Figure 4b). Furthermore, we investigated the subsets of effector cells that showed cytotoxicity against B16F10 cells by *in vivo* depletion analysis. CD4^+ or CD8^+ T cell-depleted mice were established by injecting ascites fluid from anti-CD4 or anti-CD8 hybridoma-bearing mice. NK cell-depleted mice were established by injection with anti-asialo GM1. As shown in Figure 4c, the efficiency of tumor inhibition was greatly reduced in CD8^+ T cell- and NK cell-depleted mice. However, inhibition of tumor growth was still observed in CD4^+ T cell-depleted mice. These results suggest that the antitumor effects of BV-DCs against mouse melanoma, as well as their cytotoxic effector functions, were dependent on CD8^+ T cells and NK cells.

Levels of ALT, AST and creatinine were not increased in BV-DC-inoculated mice

The wild-type baculovirus-induced activation of host immunity and the inhibition of tumor growth are shown in Figure 1b,^{20,21} however, mice treated with wild-type baculovirus also exhibited increased levels of serum ALT, AST and creatinine. We further investigated whether ALT, AST and creatinine increased in response to the administration of BV-DCs. Mice were injected intravenously with 1×10^6 cells/mouse of BV-DCs or 5×10^7 pfu/mouse of wild-type baculovirus. After 24 h, the sera were collected, and the concentrations of AST, ALT and creatinine were measured (Figure 5). BV-DC administration did not increase serum levels of ALT, AST or creatinine, and the administration of wild-type baculovirus increased only serum creatinine and not ALT and AST. This result is presumably due to the low virus titer (5×10^7 pfu) administered in the present study; other studies employed a higher virus titer ($> 1 \times 10^9$ pfu).^{21,34} These results indicate that the administration of BV-DCs did not impair liver and kidney functions in mice.

DISCUSSION

Recent clinical research on cancer immunotherapy performed in cancer patients worldwide¹ has investigated lymphocyte activation therapy, NK cell therapy, biological response modifier therapy, antibody therapy and DC therapy. In particular, research has focused on DC therapy because DCs initiate both innate and antigen-specific immune responses. Various methods are used to activate DCs, including tumor cell lysates, CpG-oligodeoxynucleotide (CpG-ODN), cytokines and viral vectors.^{25–29} Several groups have reported that viral vectors, including adenoviral and retroviral vectors, infect DCs and subsequently, infected DCs express tumor antigens and undergo maturation. Tumor growth is inhibited by inoculation of such tumor antigen-expressing DCs in tumor-bearing mice. However, in humans, the presence of neutralizing antibodies against adenovirus has necessitated immunization with a high titer of virus. Retrovirus vectors are considered unsafe because they can integrate into the host genome. Furthermore, immunotherapy with deactivated DCs does not suppress various cancers. Therefore, we examined the requirement for DC activation to induce effective antitumor activity with guaranteed safety in humans.

Baculoviruses have been widely studied as a new viral vector. In particular, studies have reported the development of various antigen-expressing baculoviruses that target specific infections.^{11–15} The recombinant baculovirus vectors strongly induced host innate and acquired immunity. We have previously reported that wild-type baculovirus induces antitumor immunity.²¹ We also showed that DCs are the immune cells most efficiently infected with baculovirus and that baculovirus-infected DCs trigger the activation of NK cells and T cells.²²

The current study demonstrated that baculovirus-infected DCs inhibited lung cancer and melanoma in mice. First, we investigated the efficacy of BV-DCs in the inhibition of mouse lung cancer. BMDCs were infected with baculovirus at an MOI of 50. We optimized the virus titer as previously reported.²² Mice used as a model for lung cancer showed inhibition of tumor growth in response to inoculation with BV-DCs (Figures 1b–d and 2a). Taura *et al.* reported a similar experiment in which they induced antitumor immunity using α -galactosylceramide-activated DCs against LLCs; however, they used fewer tumor cells (4×10^5 cells/mouse) and numerous DCs (3×10^6 cells/mouse) were inoculated.³⁰ Furthermore, DCs were injected 1 day after




Figure 3 BV-DCs mediate antitumor immunity against melanoma. B16F10 cells were subcutaneously injected into mice (1×10^6 cells/mouse) on day 0, followed by three intratumor injections (1×10^6 cells/mouse) of iDCs, CpG-DCs or BV-DCs on days 10, 17 and 24. Tumor volume was measured every 3 days. (a) Experimental design used to assess the antitumor immunity of various DCs. (b) Tumor volumes were calculated over time in BMDC-treated mice. Ten days after tumor inoculation, BMDCs were intratumorally injected into each mouse. BMDCs were inoculated three times at weekly intervals. (c) Characterization of the established B16F10 tumor. (d) Survival rate of B16F10 melanoma tumor-bearing mice treated with various BMDCs. * $P < 0.01$, compared with the negative control and iDC treatment. ** $P < 0.05$, compared with the CpG-DC treatment. Similar results were obtained in two independent experiments. BMDC, bone marrow-derived dendritic cell; BV-DC, baculovirus-infected bone marrow-derived dendritic cell; CpG-DC, CpG ($1 \mu\text{M}$)-treated bone marrow-derived dendritic cell; DC, dendritic cell; iDC, immature dendritic cell; M.O.I, multiplicity of infection; NC, negative control.

tumor inoculation. Previous reports showed that wild-type baculovirus could induce innate and acquired immunity,^{21,31} and similar results were obtained in the present study using BV-DCs (Figure 2b and c). However, the use of baculovirus in clinical applications for humans is still being analyzed, and there remain some obstacles to overcome, such as safety concerns and optimal dose, before baculovirus can be approved for use in tumor therapy. Here, we examined the antitumor effects of BV-DCs against established tumors in mice. Intratumoral injection of BV-DCs inhibited tumor growth and prolonged survival (Figure 3b–d). Western blot analysis using anti-gp64 mAb to detect baculovirus gp64 in the lysates of BV-DCs at 1 and 3 h post-infection showed the degradation and clearance of baculovirus 3 h post-infection in BMDCs (Supplementary Figure 1). This result indicates that the antitumor activity of BV-DCs is mediated by the BV-DCs and not by the remaining virus. The spleens of immunized mice exhibited increased cytotoxicity against B16F10 cells (Figure 4a). In Figure 4b, EL4 target cells showed a negative result. Our results demonstrate that CpG-DCs could inhibit LLC, but not melanoma, whereas

BV-DCs inhibited the growth of both tumor types. Therefore, we considered concluded that the inhibition of tumor growth by CpG-DCs is tumor cell type-dependent. To analyze the involvement of specific immune cell types in this tumor inhibition, CD4^+ and CD8^+ T cell- and NK cell-depleted mice were produced by injecting mice intraperitoneally with specific neutralizing antibodies. BV-DCs were inoculated into CD4^+ and CD8^+ T cell- and NK cell-depleted tumor-bearing mice. CD8^+ T cell- or NK cell-depleted mice showed a reversed effect on the inhibition of tumor growth (Figure 4c). We therefore speculated that antitumor immunity is dependent on CD8^+ T cells or NK cells but not on CD4^+ T-cell activity. Several groups have reported that regulatory T cells ($\text{CD4}^+\text{CD25}^+\text{Foxp3}^+$) are induced by tumor cells and inhibit antitumor immunity, whereas other groups have reported an inhibitory effect of tumor cells that suppresses the host antitumor immune response.^{32–34} Our data suggest that regulatory T cells may inhibit tumor growth suppression. Previously, we and other groups reported that wild-type baculovirus impairs liver function in mice.^{21,35} As shown in Figure 5, BV-DCs did




Figure 4 BV-DCs show increased cytotoxicity against B16F10 melanoma cells and depletion of CD8⁺ T cells or NK cells leads to decreased survival of immunized mice. B16F10 cells were subcutaneously injected into mice (1×10^6 cells/mouse) on day 0, followed by three intratumoral injections (1×10^6 cells/mouse) of iDCs, CpG-DCs or BV-DCs on days 10, 17 and 24. Splenocytes were isolated from immunized mice 7 days after the first immunization with BMDCs, and a cytotoxicity assay was performed. Cytotoxicity against B16F10 (a) or EL4 cells (b) by splenocytes from tumor-bearing mice treated with various BMDCs. (c) Depletion of CD4⁺, CD8⁺ or NK cells by treatment with specific antibodies. Tumor-inoculated mice were intraperitoneally injected with ascites from hybridoma-bearing mice or anti-asialo GM1. The experimental schedule is described in the section on 'Materials and methods'. * $P < 0.01$, compared with the negative control, anti-CD8 antibody-treated mice and anti-asialo GM1-treated mice. ** $P > 0.05$, compared with anti-CD4 antibody-treated mice. Similar results were obtained in two independent experiments. BMDC, bone marrow-derived dendritic cell; BV-DC, baculovirus-infected bone marrow-derived dendritic cell; CpG-DC, CpG ($1 \mu\text{M}$)-treated bone marrow-derived dendritic cell; iDC, immature dendritic cell; NC, negative control; NK, natural killer.




Figure 5 Serum AST, ALT and creatinine levels in BV-DC-immunized mice. Wild-type baculovirus or BV-DC was intravenously inoculated into mice. The sera were collected after 24 h, and AST (a), ALT (b) and creatinine (c) levels were measured. * $P > 0.05$, compared with the negative control and wild-type baculovirus treatment. ** $P < 0.05$, compared with wild-type baculovirus treatment. Similar results were obtained in two independent experiments. BV, baculovirus; BV-DC, baculovirus-infected bone marrow-derived dendritic cell; ALT, alanine aminotransferase; AST, aspartate aminotransferase.

not cause any impairment of mouse liver or kidney functions; therefore, we consider BV-DCs to be safer and more effective than wild-type baculovirus.

In summary, we showed that BV-DCs induced antitumor immunity against established tumors in mice. These antitumor effects were CD8⁺ T cell- and NK cell-dependent but CD4⁺ T cell-independent. Therefore, BV-DCs might be a useful tool for immunotherapy against malignancies.

Note: Supplementary information is available on the Cellular & Molecular Immunology website (<http://www.nature.com/cmi/>).

ACKNOWLEDGEMENTS

We thank Y. Kato, K. Kondo and Y. Goto for excellent technical assistance. This work was supported in part by a grant from the Supporting Program for Creating University Ventures from the Japan Science and Technology Agency; a grant from the Research and Development Program for New Bio-industry

Initiatives from the Ministry of Agriculture and Forestry and the Fisheries of Japan; a Grant-in-Aid for High Technology Research (No. 09309011) from the Ministry of Education, Science, Sports, and Culture, Japan; and by a Grant-in-Aid for AIDS research from the Ministry of Health, Labor and Welfare, Japan.

- 1 Aarntzen EH, Figdor CG, Adema GJ, Punt CJ, de Vries IJ. Dendritic cell vaccination and immune monitoring. *Cancer Immunol Immunother* 2008; 57: 1559–1568.
- 2 Huser A, Hofmann C. Baculovirus vectors: novel mammalian cell gene-delivery vehicles and their applications. *Am J Pharmacogenomics* 2003; 3: 53–63.
- 3 Stewart LM, Hirst M, López-Ferber M, Merryweather AT, Cayley PJ, Possee RD. Construction of an improved baculovirus insecticide containing an insect-specific toxin gene. *Nature* 1991; 352: 85–88.
- 4 Jennifer SC, Mark LH, Trevor W, Rosemary SH, David G, Bernadette MG *et al*. Field trial of a genetically improved baculovirus insecticide. *Nature* 1994; 370: 138–140.
- 5 Berger I, Fitzgerald DJ, Richmond TJ. Baculovirus expression system for heterologous multiprotein complexes. *Nat Biotechnol* 2004; 22: 1583–1587.

- 6 Matsuura Y, Possee RD, Overton HA, Bishop DH. Baculovirus expression vectors: the requirements for high level expression of proteins, including glycoproteins. *J Gen Virol* 1987; **68**: 1233–1250.
- 7 Song SU, Boyce FM. Combination treatment for osteosarcoma with baculoviral vector mediated gene therapy (p53) and chemotherapy (adriamycin). *Exp Mol Med* 2001; **33**: 46–53.
- 8 Yia-Herttuaia S, Alitalo K. Gene transfer as a tool to induce therapeutic vascular growth. *Nat Med* 2003; **9**: 694–701.
- 9 Tjia ST, zu Altschiltschesche GM, Doerfler W. Autographa californica nuclear polyhedrosis virus (AcNPV) DNA does not persist in mass cultures of mammalian cells. *Virology* 1983; **125**: 107–117.
- 10 Condreay JP, Witherspoon SM, Clay WC, Kost TA. Transient and stable gene expression in mammalian cells transduced with a recombinant baculovirus vector. *Proc Natl Acad Sci USA* 1999; **96**: 127–132.
- 11 Abe T, Takahashi H, Hamazaki H, Miyano-Kurosaki N, Matsuura Y, Takaku H. Baculovirus induces an innate immune response and confers protection from lethal influenza virus infection in mice. *J Immunol* 2003; **171**: 1133–1139.
- 12 Liqun L, Yu L, Kwang J. Baculovirus surface-displayed hemagglutinin of H5N1 influenza virus sustains its authentic cleavage, hemagglutination activity, and antigenicity. *Biochem Biophys Res Commun* 2007; **358**: 404–409.
- 13 Yang DG, Chung YC, Lai YK, Lai CW, Liu HJ, Hu YC. Avian influenza virus hemagglutinin display on baculovirus envelope: cytoplasmic domain affects virus properties and vaccine potential. *Mol Ther* 2007; **15**: 989–996.
- 14 Strauss R, Hüser A, Ni S, Tuve S, Kiviat N, Sow PS *et al*. Baculovirus-based vaccination vectors allow for efficient induction of immune responses against *Plasmodium falciparum* circumsporozoite protein. *Mol Ther* 2007; **15**: 193–202.
- 15 Fan H, Pan Y, Fang L, Wang D, Wang S, Jiang Y *et al*. Construction and immunogenicity of recombinant pseudotype baculovirus expressing the capsid protein of porcine circovirus type 2 in mice. *J Virol Methods* 2008; **150**: 21–26.
- 16 Abe T, Hemmi H, Moriishi K, Tamura S, Takaku H, Akira S *et al*. Involvement of the Toll-like receptor 9 signaling pathway in the induction of innate immunity by baculovirus. *J Virol* 2005; **79**: 2847–2858.
- 17 Abe T, Kaname Y, Wen X, Tani H, Moriishi K, Uematsu S *et al*. Baculovirus induces type I interferon production through toll-like receptor-dependent and -independent pathways in a cell-type specific manner. *J Virol* 2009; **83**: 7629–7640.
- 18 Schütz A, Scheller N, Breinig T, Meyerhans A. The *Autographa californica* nuclear polyhedrosis virus AcNPV induces functional maturation of human monocyte-derived dendritic cells. *Vaccine* 2006; **24**: 7190–7196.
- 19 Hervas-Stubbs S, Rueda P, Lopez L, Leclerc C. Insect baculoviruses strongly potentiate adaptive immune responses by inducing type I IFN. *J Immunol* 2007; **178**: 2361–2369.
- 20 Jordan KR, McMahan RH, Oh JZ, Pipeling MR, Pardoll DM, Kedi RM *et al*. Baculovirus-infected insect cells expressing peptide–MHC complexes elicit protective antitumor immunity. *J Immunol* 2008; **180**: 188–197.
- 21 Kitajima M, Abe T, Miyano-Kurosaki N, Taniguchi M, Nakayama T, Takaku H. Induction of natural killer cell-dependent antitumor immunity by the *Autographa californica* multiple nuclear polyhedrosis virus. *Mol Ther* 2008; **16**: 261–268.
- 22 Suzuki T, Chang MO, Kitajima M, Takaku H. Baculovirus activates murine dendritic cells and induces non-specific NK cell and T cell immune responses. *Cell Immunol* 2010; **262**: 35–43.
- 23 Inaba K, Inaba M, Romani N, Aya H, Oeguchi M, Ikehara S *et al*. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. *J Exp Med* 1992; **176**: 1693–1702.
- 24 Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H *et al*. A Toll-like receptor recognizes bacterial DNA. *Nature* 2000; **408**: 740–745.
- 25 Yoneyama Y, Ueda Y, Akutsu Y, Matsunaga A, Shimada H, Kato T *et al*. Development of immunostimulatory virotherapy using non-transmissible sendai virus-activated dendritic cells. *Biochem Biophys Res Commun* 2007; **355**: 129–135.
- 26 Boudreau JE, Bridle BW, Stephenson KB, Jenkins KM, Brunellière J, Bramson LJ *et al*. Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity. *Mol Ther* 2009; **17**: 1465–1472.
- 27 Metharom P, Ellem KA, Schmidt C, Wei MQ. Lentiviral vector-mediate tyrosinase-related protein 2 gene transfer to dendritic cells for therapy of melanoma. *Hum Gene Ther* 2001; **12**: 2203–2213.
- 28 Osada T, Woo CY, McKinney M, Yang XY, Lei G, Labreche HG *et al*. Induction of Wilms tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine. *Clin Cancer Res* 2009; **15**: 2789–2796.
- 29 Du YC, Zhang J, Lu YR, Ning QZ, Wang Q. Fusion of CpG-ODN-stimulating dendritic cells with lewis lung cancer cells can enhance anti-tumor immune responses. *Tissue Antigens* 2006; **67**: 368–376.
- 30 Toura I, Kawano T, Akutsu Y, Nakayama T, Ochiai T, Taniguchi M. Inhibition of experimental tumor metastasis by alpha-galactosylceramide. *J Immunol* 1999; **163**: 2387–2391.
- 31 Kitajima M, Takaku H. Induction of antitumor acquired immunity by baculovirus autographa californica multiple nuclear polyhedrosis virus infection in mice. *Clin Vaccine Immunol* 2008; **15**: 376–378.
- 32 Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T *et al*. FOXP3⁺ regulatory T cells affect the development and progression of hepatocarcinogenesis. *Clin Cancer Res* 2007; **13**: 902–911.
- 33 Steitz J, Bruck J, Lenz J, Knop J, Tuting T. Depletion of CD25⁺ CD4⁺ T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8⁺ T-cell-dependent immune defense of B16 melanoma. *Cancer Res* 2001; **61**: 8643–8646.
- 34 Shibata S, Okano S, Yonemitsu Y, Onimura M, Sata S, Nagata-Takeshita H *et al*. Induction of efficient antitumor immunity using dendritic cells activated by recombinant Sendai virus and its modulation by exogenous IFN-beta gene. *J Immunol* 2006; **177**: 3564–3576.
- 35 Kaikkonen MU, Maatta AI, Ylä-Herttuaia S, Airenne KJ. Screening of complement inhibitors: shielded baculoviruses increase the safety and efficacy of gene delivery. *Mol Ther* 2010; **18**: 987–992.



Baculovirus activates murine dendritic cells and induces non-specific NK cell and T cell immune responses

Tomoyuki Suzuki^a, Myint Oo Chang^b, Masayuki Kitajima^c, Hiroshi Takaku^{a,b,*}

^a Department of Life and Environmental Sciences, Chiba Institute of Technology, 2-17-1 Tsudanuma, Narashino, Chiba 275-0016, Japan

^b High Technology Research Center, Chiba Institute of Technology, 2-17-1 Tsudanuma, Narashino, Chiba 275-0016, Japan

^c Immunology Program, Benaroya Research Institute, Virginia Mason 1201, Ninth Avenue Seattle, WA 98101-2795, USA

ARTICLE INFO

Article history:

Received 18 August 2009

Accepted 11 December 2009

Available online 16 December 2009

Keywords:

Baculovirus
Dendritic cell
Cytokines
Cytotoxicity
Ex vivo

ABSTRACT

We previously reported that the baculovirus induced a strong host immune response against infections and malignancies. Among the immune cells, the dendritic cells were most strongly infected and activated by the baculovirus, although the exact mechanism remained unclear. Here, we evaluated the non-specific immune responses of bone marrow-derived dendritic cells (BMDCs) after infection by a wild-type baculovirus. MHC class I and II molecules and co-stimulation molecules (CD40, CD80, and CD86) on BMDCs were up-regulated by baculovirus infection. At the same time, the BMDCs produced pre-inflammatory cytokines (IL-6, IL12p70, and TNF- α) and IFN- α . NK cells showed IFN- γ production, CD69 up-regulation, and enhanced cytotoxicity when they were co-cultured with baculovirus-infected BMDCs. T cells showed IFN- γ production, CD69 up-regulation, and cell proliferation. *Ex vivo* analysis performed *in vitro* produced similar results. These findings suggested that baculovirus-infected dendritic cells induce non-specific immune responses and can be used as an immunotherapeutic agent against viral infections and malignancies, together with present therapeutic drug regimens.

© 2009 Elsevier Inc. All rights reserved.

1. Introduction

The *Autographa californica* multiple nuclear polyhedrosis virus (AcMNPV) is an enveloped insect virus (baculovirus) with a circular double-stranded DNA genome of approximately 130 kbp in length [1]. Baculoviruses have been used extensively in recombinant protein-expression systems [2,3] and as biopesticides [4,5]. Recently, the use of baculoviruses as vectors in gene therapy has been investigated [6,7]. Baculoviruses infect a range of mammalian cell types, but do not replicate [8] and can express foreign genes under the control of mammalian specific promoters [9]. When these cells are infected by baculoviruses, the viral envelope protein gp64 binds to phosphatidyl inositol on the cell surface, and the baculovirus is incorporated into the intracellular compartment by endocytosis [10]. GFP, luciferase, and other reporter genes inserted into recombinant baculoviruses can be expressed *in vitro* in mammalian cells as well as *in vivo* in animals [11]. Several previous articles have reported on baculoviruses that have been developed as

vaccines against the influenza virus [12,13], the avian influenza virus [14], malaria [15], and other diseases [16]. Facciabene et al. reported that HCV E2 protein expressing recombinant baculovirus vector induced antigen specific CD8⁺ T cell in mice [17]. Shan et al. [18] reported that a recombinant baculovirus containing the Epstein-Barr virus nuclear antigen-1 (EBNA-1) gene could express foreign genes for long periods of time in mammalian cells. Recently, Abe et al. [19] reported baculovirus-induced host-cell activation through Toll-like receptor 9 (TLR9). TLR9 was shown to recognize unmethylated CpG sequences, comprising single-stranded DNAs of approximately 20 bp in length, which are abundant within the baculovirus genome. Dendritic cells (DCs) are the most potent antigen-presenting cells of the immune system, and play pivotal roles in the initiation and maintenance of immune responses against viruses [20]. NK cells are the primary effector cells of the innate immune system, and are important for the immunological control of virus infection and tumors via the production of cytokines, mainly IFN- γ , and the potent lysis of transformed or infected cells without prestimulation [21]. Here, we demonstrated that baculovirus infects DCs more potently than other immune cells, and induced anti-tumor effects via immune activation [22]. The relationships among the immune responses of DCs and other immune cells are not fully understood. We therefore, investigated the non-specific immune responses of baculovirus-infected DCs, and the relationship between activated DCs, CD4⁺ and CD8⁺ T cells, and NK cells.

Abbreviations: BMDC, bone marrow-derived dendritic cell; DC, dendritic cell; ELISA, enzyme-linked immunosorbent assay; iDC, immature dendritic cell; MOI, multiplicity of infection.

* Corresponding author. Address: Department of Life and Environmental Sciences, Chiba Institute of Technology, 2-17-1 Tsudanuma, Narashino, Chiba 275-0016, Japan. Fax: +81 47 471 8764.

E-mail address: hiroshi.takaku@it-chiba.ac.jp (H. Takaku).

2. Materials and methods

2.1. Mice, cell lines, and reagents

Female C57BL/6 mice (6 weeks old) were purchased from Nippon SLC (Hamamatsu, Japan), and kept under humane conditions according to the rules and regulations of our institutional committee. *Spodoptera frugiperda* (Sf-9) cells were cultured at 27 °C in BD BaculoGold Medium (Invitrogen, Carlsbad, CA). The YAC-1 mouse lymphoma cell line was obtained from the Riken Cell Bank (Wako, Saitama, Japan) and maintained in RPMI-1640 (Sigma Chemical Co., St. Louis, MO) supplemented with 10% FBS (Sigma Chemical Co.), 100 U/ml penicillin, and 100 µg/ml streptomycin (Sigma Chemical Co.). LPS was bought from Sigma Chemical Co. Synthesized CpG-A (ODN-D19) was purchased from Hokkaido System Science (Sapporo, Hokkaido, Japan). Recombinant murine GM-CSF and murine IL-4 were bought from Pepro Tech EC Ltd. (London, UK). Anti-gp64 mouse IgG, FITC-conjugated anti-mouse CD11c, CD3, and CD69, and PE-conjugated anti-mouse CD40, CD80, CD86, H-2k^b, MHC-II, NK 1.1, CD4, and CD8 were purchased from eBioscience (San Diego, CA) and BD Bioscience (San Diego, CA).

2.2. Purification of wild-type baculovirus

Wild-type baculovirus was purchased from BD Bioscience, multiplied on a large scale using Sf-9 insect cells, and purified as follows: culture supernatants were harvested 3–4 days after infection, and cell debris was removed by centrifugation at 3000 rpm for 5 min. The virus was pelleted by ultracentrifugation at 25,000 rpm for 60 min at 4 °C, and then resuspended in 1 ml sterile physiological saline (PSS). The infectious titer was determined by a plaque assay.

2.3. Generation of murine bone marrow-derived DCs (BMDCs)

Murine BMDCs were generated as described previously [23]. Briefly, bone-marrow cells were harvested from the tibiae and femurs of C57BL/6 mice, and were depleted of RBCs using RBC lysis buffer (Sigma Chemical Co.). Bone-marrow cells ($2.0\text{--}3.0 \times 10^7$) were cultured in a volume of 10 ml RPMI-1640 medium containing 10% FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine (Invitrogen), and 50 µM 2-mercaptoethanol (Invitrogen), supplemented with 20 ng/ml murine GM-CSF and 20 ng/ml murine IL-4 in a 100 mm dish. On day 3, all of the culture medium was replaced by fresh medium supplemented with murine GM-CSF and murine IL-4 at the same concentration. On day 5, one-half of the culture medium was replaced by fresh medium containing murine GM-CSF and murine IL-4. On day 7, non-adherent and loosely adherent cells were harvested, and positively selected by anti-mouse CD11c microbeads (Miltenyi Biotech, Bergisch Gladbach, Germany).

2.4. Immunofluorescence staining

BMDCs (2.0×10^6) were infected with the baculovirus at a multiplicity of infection (MOI) of 50 for 4 h. Cells were fixed with 2% paraformaldehyde for 20 min at room temperature, washed with PBS including 0.1% Tween 20, permeabilized with 0.2% Triton X/PBS for 15 min at room temperature, and then washed again. The cells were incubated with anti-gp64 mouse IgG (1:50 dilution) as a primary Ab for 1 h at room temperature, washed three times, blocked with goat serum for 15 min at room temperature, and then washed again. The cells were incubated with goat anti-mouse IgG FITC (1:300 dilution) as a secondary Ab for 1 h at room tempera-

ture, followed by three washes. Baculovirus infection was visualized using fluorescence microscopy.

2.5. PCR analysis

Total DNA was extracted from each cell with the GenElute™ mammalian genomic DNA miniprep kit (Sigma Chemical Co.), according to the manufacturer's instructions, and total DNA was used for PCR analysis. Baculovirus DNA was detected by PCR using the virus DNA specific primers 5'-CTACTAGTAAATCAGTCACACC-3' (sense) and 5'-CCAAGTTTTTAATCTTGACGG-3' (antisense). The PCR amplification conditions were as follows: a denaturation step at 94 °C for 2 min, followed by 30 cycles of 94 °C for 15 s, 60 °C for 30 s, and 68 °C for 10 s (virus DNA) or 30 s (G3PDH). Each reaction was done in a volume of 25 µl with 10 ng template DNA.

2.6. Cell-viability assay

BMDCs were infected with the baculovirus at MOI values ranging from 1 to 100. After 48 h, the cells were harvested and their viability was measured by Trypan blue staining.

2.7. Flow-cytometry analysis

BMDCs (1×10^6 /well) were incubated with the baculovirus at an MOI of 50, LPS (1 µg/ml), or CpG (1 µg/ml) for 48 h. PE-conjugated anti-H2K^b, MHC class II, CD40, CD80, or CD86, and FITC-conjugated anti-CD11c (BD Bioscience and eBioscience) mAbs were used as primary mAbs. The cells were harvested, washed, and blocked using anti-mouse CD16/32 mAb (BD Bioscience) for 10 min at 4 °C. The cells were washed and incubated with primary Abs for 1 h at 4 °C. Thereafter, the cells were washed and analyzed using FACSCalibur with the CellQuest software (BD Bioscience).

2.8. ELISA

BMDCs (1×10^6 /well) were incubated with the baculovirus at an MOI of 50, LPS (1 µg/ml), or CpG (1 µg/ml) for 48 h. The culture medium was harvested, and the concentrations of mouse IFN- α , IFN- γ , IL-6, IL-10, IL-12p70, and TNF- α were measured using the respective ELISA kits (Biosource) according to the manufacturer's protocols.

2.9. Co-cultures of DC–NK cells and DC–T cells

NK cells were purified from mice spleens using the mouse NK-cell isolation kit (Miltenyi Biotech). BMDCs (5.0×10^4 /well) were infected with the wild-type baculovirus at an MOI of 50, incubated for 1 h at 37 °C, and washed with PBS. NK cells (1.0×10^5 /well) were then added to the culture for 18 h. CD4⁺ and CD8⁺ T cells were purified from mouse spleens using the mouse CD4⁺ T cell isolation kit or the mouse CD8⁺ T cell isolation kit (Miltenyi Biotech). BMDCs (1.0×10^4 /well) were infected with the baculovirus at an MOI of 50, incubated for 1 h, and washed. Anti-TCR $\alpha\beta$ Ab (0.5 µg/ml) was added and cultured for 24 h. The culture medium was harvested, and the concentration of IFN- γ was measured using the mouse IFN- γ ELISA kit (Biosource) according to the manufacturer's protocol.

2.10. In vitro cytotoxicity assay

Splenic NK cells were co-cultured with baculovirus-infected BMDCs and used as effector cells. YAC-1 cells (2×10^4) were used as target cells. BMDCs were infected with the baculovirus at an MOI of 50, incubated for 1 h at 37 °C, and washed with PBS. Thereafter, BMDCs were added to the NK-cell culture at a DC/NK ratio of

1:2 for 18 h. The cells were then co-cultured at E:T ratios of 10, 5, or 2.5 for 4 h, and the cytotoxicity was examined using the CytoTox 96 non-radioactive cytotoxicity assay kit (Promega, Madison, WI) according to the manufacturer's protocol.

2.11. Cell-proliferation assay

CD4⁺ and CD8⁺ T cells were purified from mouse spleens using the mouse CD4⁺ T cell isolation kit or the mouse CD8⁺ T cell isolation kit (Miltenyi Biotec). BMDCs (1.0×10^4 /well) were infected with the baculovirus at an MOI of 50, incubated for 1 h, and then washed with PBS. Thereafter, CD4⁺ T cells or CD8⁺ T cells (1.0×10^5 /well) were added and cultured for 48 h. Cell proliferation was determined using the CellTiter 96 Aqueous One Solution cell-proliferation assay kit (Promega) according to the manufacturer's protocol.

2.12. RT-PCR

BMDCs were infected with the baculovirus at an MOI of 50. After 6 h, total RNA was extracted from each cell with the GenElute™ mammalian genomic RNA kit (Sigma Chemical Co.) according to the manufacturer's instructions. RT-PCR was then performed using an RT-PCR high-plus kit (Toyobo, Osaka, Japan) according to the manufacturer's protocol. Rae-1, H60, and Qa-1 genes were detected by RT-PCR using the following specific primers: 5'-GAAGTGGGGGATGTTTGACACAACC-3' (sense) and 5'-GGACCTTGAGGTTGATCTTGGCTTTTC-3' (antisense) for Rae-1; 5'-TCTGGGCCATCAACACTGATGAACAG-3' (sense) and 5'-CACCAAGCGAATACCATGAATGCCA-3' (antisense) for H60; and 5'-TCCAAAGGCATGTGACCCATCA-3' (sense) and 5'-GCACCATAGCTCCAAATGATGACCACA-3' (antisense) for Qa-1. The RT-PCR amplification conditions were as follows: reverse transcription at 60 °C for 30 min and denaturation at 94 °C for 2 min, followed by 30 cycles of 94 °C for 15 s, 60 °C for 30 s, and 68 °C for 30 s. Each reaction was carried out in a volume of 25 μ l with 500 ng total RNA.

2.13. Ex vivo experiments

BMDCs (1×10^6) were incubated with the baculovirus at an MOI of 50, LPS (1 μ g/ml), or CpG (1 μ g/ml). At 1 h after incubation, the cells were washed twice and cultured for 5 h. The cells were then harvested, washed with PSS, and suspended in 200 μ l PSS. The cells were injected i.v. into five groups of mice (with three mice per group). After 6 h, the mouse splenocytes and sera were harvested. The cells were then stained with PE-conjugated anti-NK1.1 and anti-CD3, and FITC-conjugated anti-CD69, anti-CD4, and anti-CD8 Abs before FACS analysis. The serum concentration of mouse IFN- γ was measured by an ELISA. The splenocytes and target cells (YAC-1; 2×10^4) were co-cultured at E:T ratios of 100, 50, or 25 for 4 h, and the cytotoxicity was determined.

2.14. Statistical analysis

All data are presented as the means \pm SD. Statistical analysis was performed using the Student's *t*-test.

3. Results

3.1. Baculovirus infectivity in BMDCs

Baculovirus infection of mouse splenic DCs induces the secretion of IFN- α and IL-12 [19]. Kitajima et al. [22] reported that a baculovirus could infect splenic DCs *in vivo*. However, it has not been clarified whether conventional DCs or plasmacytoid DCs produce these cytokines. In the current experiment, we used BMDCs because of the possibility of differentiation into only one phenotype. We investigated whether a baculovirus could infect BMDCs *in vitro*. The BMDCs were infected with the baculovirus at an MOI of 50, and harvested 4 h later. Baculovirus-infected BMDCs were detected by immunofluorescent staining using a primary Ab to the baculovirus envelope protein gp64 and a fluorescent-conjugated




Fig. 1. Baculovirus infectivity in BMDCs. (A) BMDCs were infected with baculovirus at an MOI of 50 and cultured for 4 h. Cells were stained with anti-gp64 Ab as a primary Ab, and anti-mouse IgG FITC as a secondary Ab. Baculovirus-infected BMDCs were analyzed by fluorescence microscopy. (B) BMDCs were infected with baculovirus at MOI values ranging from 1 to 100 and cultured for 4 h. Baculovirus-infected BMDCs were detected from total DNA by PCR. (C) BMDCs were infected with baculovirus at an MOI of 50, cultured for the indicated durations, and total DNA was extracted. The baculovirus DNA was examined by PCR analysis. (D) BMDCs were infected with baculovirus at an MOI values ranging from 1 to 100 and cultured for 48 h. Cell viability was determined by Trypan blue staining. Similar results were obtained in two independent experiments.

secondary Ab (Fig. 1A). The results suggested that the baculovirus could infect not only splenic DCs but also BMDCs. Next, we demonstrated the infectivity of the baculovirus to BMDCs. The BMDCs were infected with the baculovirus at MOI values ranging from 1 to 100. After 4 h, total DNA from baculovirus-infected BMDCs was collected, and the baculovirus DNA was detected by PCR. As shown in Fig. 1B, the baculovirus-infected BMDCs in a dose-dependent manner. We also investigated the degradation of the baculovirus DNA in the BMDCs. The BMDCs were infected with the baculovirus at an MOI of 50 and the total DNA was harvested every 1–6 days. The baculovirus DNA was detected by PCR using the total DNA. These results showed that the baculovirus DNA began to be degraded at 3 days post-infection, and had completely degraded 5 days later (Fig. 1C). Finally, we investigated the viability of baculovirus-infected BMDCs. The results suggested that the baculovirus did not have a significant cytopathic effect on the BMDCs (Fig. 1D).

3.2. Activation of baculovirus-infected BMDCs

Recent reports showed that mouse splenic DCs and human monocyte-derived DCs (MDDCs) produced inflammatory cytokines and IFN- α , and that MHC molecules and co-stimulation

molecules were up-regulated, as a result of baculovirus infection [19,22,24,25]. In the current study, we investigated whether the baculovirus could induce BMDC activation. The BMDCs were infected with the baculovirus at an MOI of 50 as a positive control, stimulated LPS, or CpG. After 48 h, the BMDCs were analyzed for the activation markers MHC I, MHC II, CD40, CD80, and CD86 by FACS, and the cytokine levels in the culture supernatant were measured by an ELISA (Fig. 2A and B). The BMDC surface markers were strongly activated by baculovirus infection. The baculovirus-infected BMDCs showed up-regulation of MHC I, MHC II, CD40, CD80, and CD86 compared with the control BMDCs. Immature BMDCs were induced to mature by the up-regulation of MHC I and MHC II upon baculovirus infection. The baculovirus-infected BMDCs produced inflammatory cytokines (IL-6, IL12p70, and TNF- α) and IFN- α at greater levels than the control BMDCs. However, the baculovirus-infected BMDCs and control BMDCs did not produce IL-10. Furthermore, the BMDCs dose-dependently produced IL-12p70 upon baculovirus infection at MOI values ranging from 1 to 100 (Fig. 2C). These results suggested that the baculovirus induced the up-regulation of activation markers on BMDCs, as well as the production of inflammatory cytokines and IFN- α .




Fig. 2. Activation of baculovirus-infected BMDCs. (A) FACS analysis of cell-surface markers on baculovirus-infected BMDCs. The BMDCs were either uninfected or infected with baculovirus at an MOI of 50, or stimulated with LPS (1 μ g/ml) or CpG (1 μ g/ml) for 48 h. The cells were stained with the respective fluorescence-conjugated Ab, and the cell-surface markers were analyzed by FACS. Filled histograms represent the unstained cells, and black lines represent the uninfected and baculovirus-infected cells and those treated with LPS or CpG, respectively. (B) Examination of cytokine production in culture supernatants. The BMDCs were either uninfected or infected with baculovirus at an MOI of 50, or stimulated with LPS (1 μ g/ml) or CpG (1 μ g/ml) for 48 h, and the cytokine production was examined by an ELISA. (C) The BMDCs were infected with baculovirus at MOI values ranging from 1 to 100 and cultured for 48 h. IL12p70 production was examined by an ELISA. All data are shown as the means \pm SD and done in triplicate experiments. Similar results were obtained in two independent experiments.

3.3. NK-cell activation by baculovirus-infected BMDCs

Previous studies reported that NK cells showed IL-2, IFN- α , and IFN- γ production, and increased cytotoxicity, when co-cultured with cytomegalovirus-infected BMDCs or TLR ligand-stimulated BMDCs [26,27]. Here, we investigated whether the activation of NK cells could be induced by co-culturing them with baculovirus-infected BMDCs. The BMDCs were infected with baculovirus at an MOI of 50, and were co-cultured with NK cells from the mouse spleen. The early activation marker CD69 was up-regulated on NK cells co-cultured for 18 h with baculovirus-infected BMDCs in comparison to NK cells alone and uninfected BMDCs (Fig. 3A). We also investigated whether NK cells showed IFN- γ production and cellular cytotoxicity against NK-sensitive YAC-1 cells (Fig. 3B and C). NK cells showed IFN- γ production and increased cytotoxicity when co-cultured with baculovirus-infected BMDCs. Andoniou et al. reported that IFN- α derived from MCMV-activated DCs as well as increased expression of NKG2D ligand in MCMV-activated DCs increases NK-cell cytotoxicity. In Fig. 2B, baculovirus-infected BMDC produced IFN- α and we suggested that BMDC-induced IFN- α up-regulates NK-cell cytotoxicity. We, therefore, evaluated whether the expression of the NKG2D ligand was up-regulated in baculovirus-infected BMDCs. The total RNA levels of the activation ligand Rae-1, H60, and the inhibitory ligand Qa-1 were examined in baculovirus-infected BMDCs by RT-PCR (Fig. 3D). The expression

of H60, but not Rae-1 and Qa-1, was increased by baculovirus infection. IFN- γ production from NK cells required IL-12 and IL-18 production from activated DCs [26]. In this regard, we investigated whether BMDCs produce IL-18 upon baculovirus infection; however, we could not detect any obvious increase in IL-18 production induced by baculovirus infection (Supplementary Figure S1). These results suggested that NK-cell activation was induced when the cells were co-cultured with baculovirus-infected BMDCs. We predicted that NK cells that were activated by baculovirus-infected BMDCs up-regulated activation markers and produced cytokines.

3.4. Baculovirus-infected BMDCs induce T cell activation

As shown in Fig. 3, we compared the immune response between baculovirus-infected BMDCs and NK cells. We then compared the immune responses between baculovirus-infected BMDCs and T cells (CD4⁺ and CD8⁺ T cells). The BMDCs were infected with the baculovirus at an MOI of 50, and were co-cultured with T cells from the mouse spleen. The CD69 expression was up-regulated on T cells co-cultured with baculovirus-infected BMDCs for 18 h in comparison with T cells alone and uninfected BMDCs (Fig. 4A). In particular, the CD69 expression increased on CD8⁺ T cells more than on CD4⁺ cells. NK cells produced IFN- γ when co-cultured with baculovirus-infected BMDCs (Fig. 3B), whereas T cells did not (Sup-




Fig. 3. Induction of NK-cell activation by baculovirus-infected BMDCs. (A) FACS analysis of CD69 expression on NK cells co-cultured with baculovirus-infected BMDCs. BMDCs were either uninfected or infected with wild-type baculovirus at an MOI of 50, and then mouse NK cells separated from spleens were added and cultured for 18 h. CD69 expression on NK cells was analyzed by FACS. (B) Examination of IFN- γ production by mouse NK cells. BMDCs were either uninfected or infected with wild-type baculovirus at an MOI of 50, and then mouse NK cells separated from spleens were added and cultured for 18 h. IFN- γ was examined by an ELISA in DC/NK co-culture supernatants. (C) Cytotoxicity assay of NK cells co-cultured with BMDC. The BMDCs were either uninfected or infected with wild-type baculovirus at an MOI of 50, and then mouse NK cells separated from spleens were added together with YAC-1 target cells at the E:T ratio indicated. After 18 h incubation, cytotoxic activity against YAC-1 was analyzed by a cytotoxicity assay kit. (D) Detection of NKG2D ligand by baculovirus-infected BMDCs. The BMDCs were either uninfected or infected with wild-type baculovirus at an MOI of 50 and cultured for 6 h. Baculovirus-infected BMDCs were detected from total RNA by RT-PCR using NKG2D ligand-specific primers. All data are shown as the means \pm SD and done in triplicate experiments. Statistical analysis was performed using the Student's *t*-test. Similar results were obtained in two independent experiments.




Fig. 4. Induction of T cell activation by baculovirus-infected BMDCs. (A) FACS analysis of CD69 expression on T cells co-cultured with baculovirus-infected BMDCs. BMDCs were either uninfected or infected with wild-type baculovirus at an MOI of 50, and then mouse T cells separated from spleens were added and cultured for 18 h. CD69 expression on T cells was analyzed by FACS. (B) IFN- γ production by mouse T cells. BMDCs were either uninfected or infected with wild-type baculovirus at an MOI of 50, and then mouse T cells separated from spleens and anti-TCR $\alpha\beta$ Ab (0.5 $\mu\text{g/ml}$) were added, and cultured for 24 h. IFN- γ expression was examined by an ELISA in DC/T cell co-culture supernatants. (C) Analysis of T cell proliferation. The BMDCs were either uninfected or infected with wild-type baculovirus at an MOI of 50, and then purified mouse CD4⁺ and CD8⁺ T cells were added and co-cultured for 48 h. T cell proliferation was investigated using a proliferation kit. All data are shown as the means \pm SD and done in triplicate experiments. Statistical analysis was performed using the Student's *t*-test. Similar results were obtained in two independent experiments.

plementary Figure S3). We investigated whether T cells produced IFN- γ after TCR stimulation using anti-TCR $\alpha\beta$ Ab. TCR-stimulated T cells produced IFN- γ when co-cultured with baculovirus-infected BMDCs, but failed to do so when co-cultured with unstimulated BMDCs or T cells alone (Fig. 4B). T cells proliferated when co-cultured with baculovirus-infected BMDCs (Fig. 4C). These results suggested that not only NK cells but also T cells were activated by baculovirus-infected BMDCs.

3.5. Immune activation of baculovirus-infected BMDCs *ex vivo*

The baculovirus strongly induced the activation of BMDCs, which in turn induced the activation of NK cells and T cells *in vitro*. Here, we investigated whether baculovirus-infected BMDCs induced the activation of NK cells and T cells *ex vivo*. The BMDCs were either stimulated with the baculovirus at an MOI of 50, LPS, or CpG, or were left unstimulated. After 6 h, the stimulated BMDCs were injected *i.v.* into syngeneic mice, and the CD69 levels were analyzed on splenic NK cells and T cells. We also evaluated the splenocyte cytotoxicity and determined the serum IFN- γ levels. The CD69 expression on NK cells and T cells was up-regulated approximately 8–10-fold by inoculation with baculovirus-infected BMDCs compared with inoculation by other stimulated BMDCs (Fig. 5A). Increased splenocyte cytotoxicity and IFN- γ production were induced by inoculation with baculovirus-infected BMDCs (Fig. 5B and C). These results suggested that baculovirus-infected BMDCs induced the activation of splenic NK and T cells *in vivo*, similar to the results reported *in vitro*.

4. Discussion

Viral vectors derived from baculovirus are commonly used as tools for producing proteins in insect cells. Baculovirus transfer vectors have also shown promise in the development of vaccines. Baculovirus is well suited to gene-therapy applications due to its low cytotoxicity in mammalian cells even at high MOIs, its inherent inability to replicate in mammalian cells, and the absence of pre-existing Abs against baculoviruses in animals. We previously reported that baculoviruses could infect DCs and B cells more potently than other immune cells, and induced the up-regulation of activation markers on DCs [22]. However, the exact mechanisms of immune activation, such as DC-induced cytokine production, and the relationship between DCs and other immune cells are still not fully understood. Here we showed that a baculovirus induced the activation of BMDCs, and that baculovirus-infected BMDCs activated NK cells and T cells more effectively than LPS-stimulated or CpG-stimulated BMDCs.

The current study demonstrated that the immune responses of DCs were induced by baculovirus infection. Initially, we investigated whether the baculovirus could infect BMDCs *in vitro*. Our results showed that the BMDCs could be infected at an MOI as low as 1 (Fig. 1A and B). Other workers have reported that baculoviruses can also infect MDDCs [25], and that foreign genes are expressed with low efficiency after recombinant baculovirus vector infection of BMDCs [15]. We previously showed that the viral genome was degraded at 5–6 days after infection in various cell lines [28]. In the current study, the baculovirus genome was degraded 5 days




Fig. 5. Induction of NK-cell and T cell activation by baculovirus-infected BMDCs *ex vivo*. (A) Analysis of the expression of activation marker CD69 by NK cells and T cells in the mouse spleen. The BMDCs were either uninfected or infected with wild-type baculovirus at an MOI of 50, or stimulated with LPS (1 μ g/ml) or CpG (1 μ g/ml) and incubated for 6 h. Activated BMDCs as well as control BMDCs were inoculated (*i.v.*) into mice, and after 6 h the splenocytes were collected for FACS analysis of activation marker CD69. (B) Cytotoxicity assay of mouse splenocytes with or without inoculation of the control or baculovirus-activated BMDCs. The BMDCs were either uninfected or infected with wild-type baculovirus at an MOI of 50 and cultured for 6 h. Each type of BMDC was inoculated (*i.v.*) into mice, and after 6 h the splenocytes were collected and mixed with the YAC-1 target cells at the E:T ratio described. Cytotoxic activity was measured by a cytotoxicity assay kit. (X) Measurement of IFN- γ production from serum. The BMDCs were either uninfected or infected with wild-type baculovirus at an MOI of 50, or stimulated with LPS (1 μ g/ml) or CpG (1 μ g/ml) and incubated for 6 h. Activated BMDCs and control BMDCs were inoculated (*i.v.*) into mice, and after 6 h the serum was harvested and IFN- γ expression was measured by an ELISA. All data are shown as the means \pm SD and done in triplicate experiments. Similar results were obtained in two independent experiments.

after infection in the BMDCs (Fig. 1C). The cytotoxicity due to the baculovirus infection was low even at higher MOIs (Fig. 1D). Previous studies have reported on the activation of DCs by baculovirus infection *in vitro* and *in vivo*. Baculovirus-infected MDDCs were shown to express cell-surface markers of activation and to produce TNF- α [25]. Mouse splenic DCs were also reported to express activated cell-surface markers and to produce cytokines upon baculovirus inoculation [22,24]. Our current results showed that BMDCs expressed activated cell-surface markers and produced inflammatory cytokines and IFNs due to baculovirus infection, but did not produce IL-10 (Fig. 2A–C). These findings suggested that the baculovirus could induce cellular immunity more potently than humoral immunity. NK cells produce IFN- γ through IL-12 and IL-18, secreted by activated DCs, and NK-cell cytotoxicity is increased through IFN- α and up-regulated NKG2D ligand expression by activated DCs [26]. We examined the production of IL-18 from baculovirus-infected BMDCs. However, we could not detect IL-18 production (Supplementary Figure S1), which was consistent with previously published reports [26]. Andoniu and coworkers suggested that IL-18 production by DCs might be restricted to the synaptic cleft [26,29]. Other authors reported that the production of IFN- γ by NK cells requires the formation of a synapse leading to IL-12 polarization in the DCs [30]. NK cells produced IFN- γ when co-cultured with baculovirus-infected BMDCs (Fig. 3B). As shown in Figs. 2A and 3B, it appeared that baculovirus-infected BMDCs produced IL-12 and NK cells produced IFN- γ . Gerosa et al. [31] reported that the expression of the early activation marker CD69 on

NK cells was up-regulated when they were co-cultured with TLR ligand-stimulated DCs. The expression of CD69 required IFN- α and IFN- β secretion by DCs, and direct interaction between DCs and NK cells. We confirmed that CD69 expression was up-regulated on NK cells by baculovirus-infected BMDCs (Fig. 3A), and that NK-cell cytotoxicity was also increased (Fig. 3C). The NKG2D ligand H60 mRNA was up-regulated by baculovirus-infected BMDCs (Fig. 3D). Andoniu et al. [26] suggested that weak expression of the NKG2D ligand on mouse cytomegalovirus (MCMV)-infected BMDCs might have been sufficient to activate NK-cell cytotoxicity. Next, we investigated the relationships between baculovirus-infected BMDCs and CD4⁺ and CD8⁺ T cells. We confirmed that CD69 expression was up-regulated on T cells by baculovirus-infected BMDCs (Fig. 4A), and that T cell proliferation was also increased (Fig. 4C), although the T cells did not produce IFN- γ (Supplementary Figure S2). Feili-Hariri et al. [32] demonstrated IFN- γ production by T cells that were stimulated with anti-TCR $\alpha\beta$ Ab. We also demonstrated that baculovirus-infected BMDCs induced IFN- γ production by T cells upon stimulation with anti-TCR $\alpha\beta$ Ab. These results suggested that T cells produced IFN- γ when co-cultured with baculovirus-infected BMDCs (Fig. 4B). By contrast, the controls without anti-TCR $\alpha\beta$ Ab showed no significant effects. Finally, we investigated whether baculovirus-infected BMDCs induced the activation of NK cells and T cells *ex vivo* as well as *in vitro*. Mouse splenic NK cells did not show CD69 activation in response to subcutaneous injection of BMDCs (Supplementary Figure S3). Eggert and coworkers reported that DCs accumulated in

the spleen more than in other organs in intravenously injected mice [33]. Unstimulated BMDCs, baculovirus-infected BMDCs, and LPS-stimulated or CpG-stimulated BMDCs were injected intravenously into respective mice, and the expression of CD69 on NK cells and T cells was examined by FACS analysis. The results suggested that the CD69 expression on splenic NK cells and T cells was up-regulated by baculovirus-infected BMDCs more than the controls (Fig. 5A), and the splenocyte cytotoxicity also increased (Fig. 5B). The presence of IFN- γ in the serum was confirmed in mice injected with baculovirus-infected BMDCs (Fig. 5C). These results indicated that baculovirus-infected BMDCs induced the non-specific activation of splenic NK cells and T cells *ex vivo*, the same as *in vitro* results. We have previously shown that wild-type baculovirus induces anti-tumor acquired immunity against challenged tumor cells in the form of increased CTL activity and tumor-specific antibody production [34].

Although specific immune responses against viral infections and tumors are the essential arm of immunity, non-specific immune responses are also reported to be an important factor in control of viral infections such as HIV infection. The presence of functional HIV-specific CTL responses and CD4⁺ T helper responses do not protect against progression to AIDS in the chronic phase of HIV infection [35]. Recently, it has been apparent that a CD8⁺ T cell-inducing vaccine has failed in a phase IIB clinical trial. The presence of high numbers of cytokine-producing HIV-specific CD8⁺ T cells does not guarantee a better clinical outcome [36]. Taking these reports into account, we emphasized to examine non-specific immune responses induced by wild-type baculovirus in this report.

In conclusion, the baculovirus induced the expression of activation markers on DCs, and the production of inflammatory cytokines (IL-6, IL-12p70, and TNF- α) and IFN- α . Furthermore, the baculovirus-infected BMDCs induced stronger activation of NK cells and T cells than LPS-stimulated or CpG-stimulated BMDCs. The NK cells showed IFN- γ production, up-regulated cytotoxicity, and CD69 expression. The T cells showed IFN- γ production, up-regulated proliferation, and increased CD69 expression. Baculovirus-infected BMDCs might therefore be a useful tool as an immunotherapy in the treatment of viral infections and malignancies to be used in association with present therapies to achieve most effective results.

Acknowledgments

We thank Y. Mori, S. Yanase, and Y. Kasai for excellent technical assistance. This work was supported, in part, by a Grant-in-Aid for High Technology Research from the Ministry of Education, Science, Sports, and Culture, Japan, and by a grant from the Research and Development Program for New Bio-industry Initiatives from the Ministry of Agriculture and Forestry, and Fisheries of Japan.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.cellimm.2009.12.005.

References

- [1] A. Huser, C. Hofmann, Baculovirus vectors: novel mammalian cell gene-delivery vehicles and their applications, *Am. J. Pharmacogenomics* 3 (2003) 53–63.
- [2] I. Berger, D.J. Fitzgerald, T.J. Richmond, Baculovirus expression system for heterologous multiprotein complexes, *Nat. Biotechnol.* 22 (2004) 1583–1587.
- [3] Y. Matsuura, R.D. Possee, H.A. Overton, D.H. Bishop, Baculovirus expression vectors: the requirements for high level expression of proteins, including glycoproteins, *J. Gen. Virol.* 68 (1987) 1233–1250.
- [4] L.M. Stewart, M. Hirst, M. López-Ferber, A.T. Merryweather, P.J. Cayley, R.D. Possee, Construction of an improved baculovirus insecticide containing an insect-specific toxin gene, *Nature* 352 (1991) 85–88.
- [5] S.C. Jennifer, L.H. Mark, W. Trevor, S.H. Rosemary, G. David, M.G. Bernadette, M.C. Timothy, D.P. Robert, P.J. Cayley, H.L. David, Field trial of a genetically improved baculovirus insecticide, *Nature* 370 (1994) 138–140.
- [6] S.U. Song, F.M. Boyce, Combination treatment for osteosarcoma with baculoviral vector mediated gene therapy (p53) and chemotherapy (adriamycin), *Exp. Mol. Med.* 33 (2001) 46–53.
- [7] S. Yla-Herttuala, K. Alitalo, Gene transfer as a tool to induce therapeutic vascular growth, *Nat. Med.* 9 (2003) 694–701.
- [8] S.Y. Tjia, G.M. zu Altenschildesche, W. Doerfler, *Autographa californica nuclear polyhedrosis virus* (AcNPV) DNA does not persist in mass cultures of mammalian cells, *Virology* 125 (1983) 107–117.
- [9] J.P. Condreay, S.M. Witherspoon, W.C. Clay, T.A. Kost, Transient and stable gene expression in mammalian cells transduced with a recombinant baculovirus vector, *Proc. Natl. Acad. Sci. USA* 96 (1999) 127–132.
- [10] H. Tani, M. Nishijima, H. Ushijima, T. Miyamura, Y. Matsuura, Characterization of cell-surface determinants important for baculovirus infection, *Virology* 279 (2001) 343–353.
- [11] T. Cheng, C.Y. Xu, Y.B. Wang, M. Chen, T. Wu, J. Zhang, N.S. Xia, A rapid and efficient method to express target genes in mammalian cells by baculovirus, *World J. Gastroenterol.* 10 (2004) 1612–1618.
- [12] T. Abe, H. Takahashi, H. Hamazaki, N. Miyano-Kurosaki, Y. Matsuura, H. Takaku, Baculovirus induces an innate immune response and confers protection from lethal influenza virus infection in mice, *J. Immunol.* 171 (2003) 1133–1139.
- [13] L. Liqun, L. Yu, J. Kwang, Baculovirus surface-displayed hemagglutinin of H5N1 influenza virus sustains its authentic cleavage, hemagglutination activity, and antigenicity, *Biochem. Biophys. Res. Commun.* 358 (2007) 404–409.
- [14] Y. Ding-Gang, C. Yao-Chi, L. Yiu-Kay, L. Chia-Wei, L. Hung-Jen, H. Yu-Chen, Avian influenza virus envelope: cytoplasmic domain affects virus properties and vaccine potential, *Mol. Ther.* 15 (2007) 989–996.
- [15] R. Strauss, A. Hüser, S. Ni, S. Tuve, N. Kiviat, P.S. Sow, C. Hofmann, A. Lieber, Baculovirus-based vaccination vectors allow for efficient induction of immune responses against *Plasmodium falciparum* circumsporozoite protein, *Mol. Ther.* 15 (2007) 193–202.
- [16] H. Fan, Y. Pan, L. Fang, D. Wang, S. Wang, Y. Jiang, H. Chen, S. Xiao, Construction and immunogenicity of recombinant pseudotype baculovirus expressing the capsid protein of porcine circovirus type 2 in mice, *J. Virol. Methods* 150 (2008) 21–26.
- [17] A. Facciabene, L. Aurisicchio, N. La Monica, Baculovirus vectors elicit antigen-specific immune responses in mice, *J. Virol.* 78 (2004) 8663–8672.
- [18] L. Shan, L. Wang, J. Yin, P. Zhong, J. Zhong, An OriP/EBNA-1-based baculovirus vector with prolonged and enhanced transgene expression, *J. Gene Med.* 8 (2006) 1400–1406.
- [19] T. Abe, H. Hemmi, K. Moriishi, S. Tamura, H. Takaku, S. Akira, Y. Matsuura, Involvement of the toll-like receptor 9 signaling pathway in the induction of innate immunity by baculovirus, *J. Virol.* 79 (2005) 2847–2858.
- [20] J. Banchemareau, R.M. Steinman, Dendritic cells and the control of immunity, *Nature* 392 (1998) 245–252.
- [21] M.A. Cooper, T.A. Fehniger, M.A. Caligiuri, The biology of human natural killer-cell subsets, *Trends Immunol.* 22 (2001) 633–640.
- [22] M. Kitajima, T. Abe, N. Miyano-Kurosaki, M. Taniguchi, T. Nakayama, H. Takaku, Induction of natural killer cell-dependent antitumor immunity by the *Autographa californica* multiple nuclear polyhedrosis virus, *Mol. Ther.* 16 (2008) 261–268.
- [23] K. Inaba, M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor, *J. Exp. Med.* 176 (1992) 1693–1702.
- [24] S. Hervas-Stubbs, P. Rueda, L. Lopez, C. Leclerc, Insect baculoviruses strongly potentiate adaptive immune responses by inducing type I IFN, *J. Immunol.* 178 (2007) 2361–2369.
- [25] A. Schütz, N. Scheller, T. Breinig, A. Meyerhans, The *Autographa californica* nuclear polyhedrosis virus AcNPV induces functional maturation of human monocyte-derived dendritic cells, *Vaccine* 24 (2006) 7190–7196.
- [26] C.E. Andoniou, S.L. van Dommelen, V. Voigt, D.M. Andrews, G. Brizard, C. Asselin-Paturel, T. Delale, K.J. Stacey, G. Trinchieri, M.A. Degli-Esposti, Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity, *Nat. Immunol.* 6 (2005) 1011–1019.
- [27] I. Zanoni, M. Foti, P. Ricciardi-Castagnoli, F. Granucci, TLR-dependent activation stimuli associated with Th1 responses confer NK cell stimulatory capacity to mouse dendritic cells, *J. Immunol.* 175 (2005) 286–292.
- [28] M. Kitajima, H. Hamazaki, N. Miyano-Kurosaki, H. Takaku, Characterization of baculovirus *Autographa californica* multiple nuclear polyhedrosis virus infection in mammalian cells, *Biochem. Biophys. Res. Commun.* 343 (2006) 378–384.
- [29] C. Semino, G. Angelini, A. Poggi, A. Rubartelli, NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1, *Blood* 106 (2005) 609–616.
- [30] C. Borg, A. Jalil, D. Laderach, K. Maruyama, H. Wakasugi, S. Charrier, B. Ruffel, A. Cambi, C. Figdor, W. Vainchenker, A. Galy, A. Caignard, L. Zitvogel, NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs, *Blood* 104 (2004) 3267–3275.

- [31] F. Gerosa, A. Gobbi, P. Zorzi, S. Burg, F. Briere, G. Carra, G. Trinchieri, The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions, *J. Immunol.* 174 (2005) 727–734.
- [32] M. Feili-Hariri, D.H. Falkner, P.A. Morel, Polarization of naive T cells into Th1 or Th2 by distinct cytokine-driven murine dendritic cell populations: implications for immunotherapy, *J. Leukoc. Biol.* 78 (2005) 656–664.
- [33] A.A. Eggert, M.W. Schreurs, O.C. Boerman, W. Oyen, A.J. de Boer, C.J. Punt, C.G. Figdor, G.J. Adema, Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration, *Cancer Res.* 59 (1999) 3340–3345.
- [34] M. Kitajima, H. Takaku, Induction of antitumor acquired immunity by baculovirus *Autographa californica* multiple nuclear polyhedrosis virus infection in mice, *Clin. Vaccine Immunol.* 15 (2008) 376–378.
- [35] C.A. Jansen, D. van Baarle, F. Miedema, HIV-specific CD4⁺ T cells and viremia: who's in control?, *Trends Immunol* 27 (2006) 119–124.
- [36] I.M. Schellens, J.A. Borghans, C.A. Jansen, I.M. De Cuyper, R.B. Geskus, D. van Baarle, F. Miedema, Abundance of early functional HIV-specific CD8⁺ T cells does not predict AIDS-free survival time, *PLoS ONE* 3 (2008) e2745.

Original article

Combination therapy for hepatitis C virus with heat-shock protein 90 inhibitor 17-AAG and proteasome inhibitor MG132

Saneyuki Ujino¹, Saori Yamaguchi¹, Kunitada Shimotohno^{2,3} and Hiroshi Takaku^{1,2,4*}¹Department of Life and Environmental Sciences, Chiba Institute of Technology, Tsudanuma, Narashino, Chiba, Japan²Research Institute, Chiba Institute of Technology, Tsudanuma, Narashino, Chiba, Japan³Center of Integrated Medical Research, School of Medicine, Keio University, Tokyo, Japan⁴High Technology Research Center, Chiba Institute of Technology, Tsudanuma, Narashino, Chiba, Japan

*Corresponding author: e-mail: hiroshi.takaku@it-chiba.ac.jp

Background: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease. Here, we report a new and effective strategy for inhibiting HCV replication using an inhibitor of heat-shock protein 90, 17-AAG (17-allylamino-17-demethoxygeldanamycin), and a proteasome inhibitor, MG132.

Methods: To explore the virological basis of combination therapy, we analysed the effects of 17-AAG and MG132, singly and in combination on HCV replication in an HCV replicon cell system.

Results: In HCV replicon cells, HCV RNA replication was suppressed by 17-AAG in a dose-dependent manner. As shown in the present study, the 50% inhibitory concentration values were 0.82 nM for 17-AAG and 0.21 nM for MG132. Low concentrations of MG132 had strong synergistic inhibitory effects with low toxicity on HCV replicon cells.

Conclusions: The results of this study suggest that the different effects and synergistic actions of 17-AAG and MG132 could provide a new therapeutic approach to HCV infection.

Introduction


Infection by the hepatitis C virus (HCV) is a major public health problem, with 170 million chronically infected people worldwide [1,2]. Combined treatment with interferon- α and ribavirin induces sustained antiviral response in 80% of patients with HCV genotype 2 or 3 [3,4]. Chronic infection with HCV results in liver cirrhosis and can lead to hepatocellular carcinoma [5,6]. Although interferon- α plus ribavirin therapy is effective for approximately 50–80% of patients with HCV, the development of improved therapies and preventative vaccines is urgently needed [7].

Heat-shock protein 90 (Hsp90) exerts chaperone activity together with a number of cochaperones, playing an important role in the folding of at least 200 specific proteins of various signalling pathways and in the refolding of proteins that have been denatured by stress [8–11]. Hsp90 is considered to be of prime importance to the survival of cancer cells. The constitutive expression of Hsp90 is 2- to 10-fold higher in tumour cells compared with their normal counterparts, suggesting that Hsp90 is critically

important for tumour cell growth and/or survival. A small molecule inhibitor of Hsp90, the benzoquinone ansamycin 17-AAG (17-allylamino-17-desmethoxygeldanamycin; Figure 1A), exhibits antitumour activity in several human xenograft models, including colon, breast and prostate cancer [12–14]. The drug is currently completing multi-institution Phase I clinical trials, and Phase II trials are being planned.

The HCV non-structural protein 3 (NS3) forms a complex with Hsp90 [8,10,11] that is critical for HCV replication [15]. Treatment of the #50-1 HCV replicon cells with the Hsp90 inhibitor 17-AAG [8,16,17] suppresses HCV RNA replication and NS3 is the only HCV protein degraded in these cells [15]. This finding led us to suggest a crucial role for Hsp90–NS3 complexes in the HCV life cycle. By contrast, the proteasome is a large protein complex that also participates in protein degradation [18]. Among the 28 subunits of the 20S proteasome, the α -subunit 7 (PSMA7) is one of the α -ring subunits at the barrel centre of the proteasome complex. The 20S proteasome is activated

Figure 1. Schematic representation of the HCV replicon and the structures of 17-AAG and MG132



(A) Structure of the heat-shock protein 90 inhibitor 17-AAG. (B) Structure of the proteasome inhibitor MG132. (C) Structure of the hepatitis C virus (HCV) replicon RNAs comprising the HCV 5'-untranslated region, including the HCV internal ribosome entry site (IRES), the neomycin phosphotransferase gene (Neor), the encephalomyocarditis virus (EMCV) IRES or the HCV IRES, and the coding region for HCV proteins NS3 to NS5B (in the HCV subgenomic replicon) or core protein to NS5B (in the HCV full-length replicon). (D) Effect of 17-AAG and MG132 on expression of the NS3 protein. β -Actin was used as a lysate control. The HCV full-length replicon (NNC#2 cells) was analysed by western blotting after 17-AAG treatment with or without MG132.

upon association with its regulatory protein complex, classified as PA700 (19S regulator) and PA28 (11S regulator) [18]. Ribozymes and small interference RNAs that specifically target the putative HCV cofactor PSMA7 inhibit HCV expression [19,20].

In the present study, we describe our findings of HCV combination therapy with the Hsp90 inhibitor 17-AAG and the proteasome inhibitor MG132 (Figure 1B). Combining these different inhibitors produced significant synergistic inhibitory effects on HCV replicons, indicating that the inhibitors might be useful as an efficient dual strategy of molecular HCV therapeutics.

Methods

Cell culture and reagents

The HCV replicon cell line #50-1 (NN/1b/SG) [21], which carries a subgenomic replicon, and NNC#2 (NN/1b/FL) [22], which carries a full genome replicon, were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, non-essential amino acids, L-glutamine, penicillin-streptomycin, and 300–1,000 µg/ml G418 (Invitrogen, Carlsbad, CA, USA) at 37°C in 5% CO₂. Huh-7 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin. 17-AAG and MG132 were purchased from Sigma-Aldrich Chemical Co. (St Louis, MO, USA).

Real-time reverse transcriptase PCR analysis

HCV replicon cells were seeded at 1.5×10^5 cells in 24-well plates and cultured for 72 h. Total RNA was then isolated using Trizol (Invitrogen) according to the manufacturer's instructions. HCV RNA was quantified by real-time reverse transcriptase (RT)-PCR using an ABI 7700 sequence detector (Perkin-Elmer Applied Biosystems, Foster City, CA, USA), and the following primers and TaqMan probes located in the 5'-untranslated region: forward primer (nucleotides [nt] 130–146), 5'-CGGGAGAGCCATAGTGG-3'; reverse primer (nt 272–290), 5'-AGTACCACAAGGCCTTTCG-3'; and TaqMan probe (nt 148–168), 5'-CTGCGGAACCGGTGAGTACAC-3' (all purchased from Applied Biosystems). The probe sequence was labelled with the reporter dye 6-carboxyfluorescein at the 5'-end and with the quencher dye TAMRA at the 3'-end [23].

Western blotting

NNC#2 cells were seeded at 1.5×10^5 cells in 24-well plates, treated with 17-AAG alone, MG132 alone, or combined 17-AAG and MG132, and cultured for 48 h. Western blotting analysis was performed using a previously described method [15]. The primary antibodies

were monoclonal or polyclonal antibodies against PSMA7 (Abcam, Cambridge, MA, USA) and β-actine (SIGMA, Sigma-Aldrich). The anticore antibody was a kind gift from M Kohara (Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan). Anti-NS3 antibody was a kind gift from Y Matsuura (Osaka University, Osaka, Japan).

Transfection and reporter assay

Huh-7 cells were seeded at 1.5×10^5 cells 24 h before transfection. Huh-7 cells were treated with MG132 (100 nM) following transfection with the plasmid DNA pHCV internal ribosome entry site (IRES) luciferase (luc) or pEMCV IRES luc using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. Luc activity was measured in the cell lysates using a luminometer (Berthold, Bad Wildbad, Germany).

MTS assay


HCV replicon cells were seeded in 96-well plates at 3×10^4 cells per well in a final culture volume of 100 µl for 72 h before adding increasing concentrations of 17-AAG and MG132. After incubation for 3 days, viable cell numbers were determined using the CellTiter 96® Aqueous non-radioactive cell proliferation assay (Promega Corp., Madison, WI, USA). The value of the background absorbance at 490 nm (A_{490}) of wells without cells was subtracted from the A_{490} value of wells with cells. The percentages of viable cells were then calculated using the following formula: $(A_{490} \text{ 17-AAG-}, \text{MG132- or 17-AAG+MG132-treated cells} / A_{490} \text{ untreated cells}) \times 100$.

Drug synergism analysis

The effect of treatment of HCV replicon cells with 17-AAG and MG132, alone and in combination, was analysed by measuring HCV RNA with real-time PCR. The combination index (CI) for each combination of 17-AAG and MG132 treatment was calculated by the following formula using the 50% inhibitory concentration (IC_{50}): $CI = IC_{50}(\text{17-AAG combined}) / IC_{50}(\text{17-AAG alone}) + IC_{50}(\text{MG132 combined}) / IC_{50}(\text{MG132 alone})$. For such plots, the combined effects of the two drugs can be assessed as either additive ($CI=1$), synergistic ($CI<1$) or antagonistic ($CI>1$) [24].

Results

In a previous study, we examined the inhibitory effects of 17-AAG on HCV replication in an HCV replicon cell culture system. In HCV replicon cells treated with 17-AAG, HCV RNA replication was suppressed in a dose-dependent manner, and the only HCV protein degraded in these cells was NS3 [15]. To determine whether 17-AAG promoted the degradation of NS3,

Figure 2. Effect of proteasome inhibitor MG132 on HCV IRES activity

(A) Vector construct for hepatitis C virus (HCV) internal ribosome entry site (IRES)-mediated (pHCV IRES luc) or encephalomyocarditis virus (EMCV) IRES-mediated (pEMCV IRES luc) translation of firefly luciferase. **(B)** Huh-7 cells were transfected with pHCV IRES luc alone or pEMCV IRES luc alone (PC), or also treated with MG132 100, 200 and 250 nM. After 24 h, HCV IRES activity was determined by luciferase assay. Data are means \pm SD of triplicate experiments.

we evaluated the effect of 17-AAG on #50-1 cells in which proteasomal degradation was also inhibited with the proteasome inhibitor MG132. Although 17-AAG treatment reduced NS3 levels in #50-1 cells, this NS3 degradation was completely blocked in the presence of MG132 [15]. In the present study, we used HCV full-length replicon NNC#2 cells (Figure 1C) [22] instead of the HCV subgenomic replicon #50-1 cells used in previous studies [15,21]. Treatment with 17-AAG decreased NS3 levels, but the presence of MG132 did not block the reduction in HCV NS3 (Figure 1D). Indeed, MG132 in combination with 17-AAG induced the complete disappearance of the NS3 (Figure 1D), suggesting that the reduction of HCV NS3 induced by treatment with the proteasome inhibitor MG132 was dependent on the HCV IRES. NNC#2 and #50-1 cells have different virus IRESs, known as the HCV IRES [25–27] and the encephalomyocarditis virus (EMCV) IRES [28], and HCV IRES-mediated translation is induced by PSMA7 [29]. The PSMA7 activity is blocked by MG132 [30]. Similar effects were observed when PSMA7-directed ribozyme or small interfering RNAs inhibited HCV replication [19,20].

We examined the effects of combination therapy with 17-AAG and MG132 on HCV. To evaluate the MG132-mediated effect on HCV IRES activity, Huh-7 cells were treated with MG132 (100, 200 and 250 nM) and then transfected with pHCV IRES luc or pEMCV IRES luc (Figure 2A). MG132 inhibited luc activity of HCV IRES in dose-dependent manner, but did not inhibit translation derived from EMCV IRES (Figure 2B), indicating

a preferential effect of MG132 on HCV IRES activity [19]. NNC#2 cells were then treated with 17-AAG or MG132 for 3 days. HCV RNA was quantified by real-time RT-PCR using an ABI 7500 Fast (Perkin-Elmer, Applied Biosystems). Dose-dependent cytotoxicity was not observed upon application of MG132 and/or 17-AAG (99% at concentrations ranging between 5 and 25 nM; Figure 3A), but was observed at MG132 concentrations of 10 μ M (data not shown). Cells treated with increasing doses of 17-AAG or MG132 showed reduced levels of HCV RNA (Figure 3B). Low concentrations (1 nM) of MG132 had inhibitory effects similar to those of 15 nM 17-AAG (Figure 3B). In NNC#2 cells treated with 5 nM MG132, HCV RNA replication was suppressed by 85%, and this effect was dose-dependent (Figure 3B). The IC_{50} values were 0.82 nM for 17-AAG and 0.21 nM for MG132 (Table 1 and Figure 3B).

We also investigated combination therapy with 17-AAG and MG132 on HCV in NNC#2 cells. In combination with 5 nM, 15 nM or 25 nM of 17-AAG, 0.5 nM, 1 nM or 5 nM of MG132 was applied to NNC#2 cells, respectively. The combination of 5 nM 17-AAG and 1 nM MG132 suppressed HCV RNA replication by 90% in the NNC#2 cells (Figure 3B). The CI was 0.42, demonstrating that 17-AAG and MG132 had synergistic inhibitory effects on HCV replicon cells (Table 1). The combination of 17-AAG with MG132 inhibited HCV RNA replication with an approximately 2.5-fold reduction in the dose (Table 1). To determine the effects of 17-AAG and MG132 on the expression of core and PSMA7 proteins, NNC#2 cells were treated